Skip to content

Search

Global molecular diversity of RSV – the “INFORM RSV” study

Respiratory syncytial virus (RSV) is a global cause of severe respiratory morbidity and mortality in infants. While preventive and therapeutic interventions are being developed, including antivirals, vaccines and monoclonal antibodies, little is known about the global molecular epidemiology of RSV. INFORM is a prospective, multicenter, global clinical study performed by ReSViNET to investigate the worldwide molecular diversity of RSV isolates collected from children less than 5 years of age.

Celebrate Book Week with Us!

Join us for stories, imagination and connection in the Discovery Centre

Decoding DNA at The Kids Research Institute Australia

Get ready for a week of mind-blowing fun as the Discovery Centre comes alive for National Science Week with this year’s exciting theme: Decoding the Universe!

Genocide in the Wildflower State Screening & Panel discussion

A powerful screening of truth telling that captures the stories of the Western Australia Stolen Generation.

Help shape the future of health & medical research in your community

Find out what our communities had to say about the draft Statement on Consumers and Community Involvement in Health and Medical Research.

Rheumatic Heart Disease Endgame Strategy: what does it mean to community?

Across Australia, more than 5,000 Aboriginal and Torres Strait Islander people are currently living with rheumatic heart disease (RHD) or its precursor, acute rheumatic fever (ARF).

Our research

At the Wesfarmers Centre, we undertake research in five key areas of infections and immunisation to assist in children's health.

PATROL RSV Study

Researchers from The Kids Research Institute Australia would like to understand more about respiratory syncytial virus (RSV) and how we can provide the best protection for kids.

Hospital-based research

Review the hospital-based research that the Wesfamers Centre of Vaccines & Infectious Diseases conducts.

Vaccine Trials Group

We are evaluating new vaccines for a range of diseases including influenza, pneumococcal, meningococcal and common infections such as otitis media (glue ear).